What to Expect From Biogen's Next Quarterly Earnings Report

Core Insights - Biogen Inc. is set to announce its fiscal Q4 earnings for 2025, with a current market cap of $26.2 billion [1] Financial Performance - Analysts expect Biogen to report a profit of $1.72 per share for Q4 2025, a decrease of 50% from $3.44 per share in the same quarter last year [2] - For the current fiscal year ending in December, the expected profit is $14.89 per share, down 9.6% from $16.47 per share in fiscal 2024, but projected to rebound to $15.01 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, Biogen's shares have increased by 18.7%, underperforming the S&P 500 Index's return of 19.7%, but outperforming the State Street Health Care Select Sector SPDR ETF's increase of 10.8% [4] - On December 19, Biogen's shares rose by 2.9% after RBC Capital reaffirmed its "Outperform" rating and maintained a $210 price target, citing stabilization in its core business and growth potential for its Alzheimer's treatment, Leqembi [5] Analyst Ratings - Wall Street analysts have a "Moderate Buy" rating for Biogen, with 14 out of 34 analysts recommending "Strong Buy," one suggesting "Moderate Buy," and 19 indicating "Hold" [6] - The mean price target for Biogen is $187.11, suggesting a potential upside of 4.9% from current levels [6]